Jill M. Quigley Net Worth

The estimated Net Worth of Jill M. Quigley is at least $814 Thousand dollars as of 8 December 2021. Jill Quigley owns over 71,975 units of Passage Bio Inc stock worth over $283,941 and over the last 5 years Jill sold PASG stock worth over $529,583.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jill Quigley PASG stock SEC Form 4 insiders trading

Jill has made over 4 trades of the Passage Bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Jill exercised 71,975 units of PASG stock worth $16,554 on 8 December 2021.

The largest trade Jill's ever made was exercising 71,975 units of Passage Bio Inc stock on 8 December 2021 worth over $16,554. On average, Jill trades about 15,346 units every 108 days since 2020. As of 8 December 2021 Jill still owns at least 368,754 units of Passage Bio Inc stock.

You can see the complete history of Jill Quigley stock trades at the bottom of the page.

What's Jill Quigley's mailing address?

Jill's mailing address filed with the SEC is ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA, PA, 19103.

Insiders trading at Passage Bio Inc

Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit..., and Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.

What does Passage Bio Inc do?

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou

Complete history of Jill Quigley stock trades at Passage Bio Inc

Passage Bio Inc executives and stock owners

Passage Bio Inc executives and other stock owners filed with the SEC include:

• Dr. Bruce A. Goldsmith M.B.A., Ph.D.,
  CEO, Pres & Director
• Dr. Maxine Gowen M.B.A., Ph.D.,
  Interim Exec. Chairwoman
• Desiree Luthman D.D.S.,
  Sr. VP of Global Regulatory Affairs
• Dr. Mark Forman M.D., Ph.D.,
  Chief Medical Officer
• Monika Tornsen,
  Chief Commercial Officer
• Gregory Fuest,
  VP of Global Commercial Strategy & Marketing
• Alexandros Fotopoulos MBA, MSc,
  Chief Technical Officer
• Monika Maria Tornsen,
  Chief Commercial Officer
• Dr. Eliseo Oreste Salinas M.D., M.Sc.,
  Chief R&D Officer
• Robin DeRogatis M.B.A.,
  Sr. VP HR
• Gwen Fisher M.B.A.,
  VP of Corp. Communications
• Edgar B. Cale Esq., J.D.,
  Gen. Counsel & Company Sec.
• Stuart M. Henderson,
  VP Investor Relations & Strategic Fin.
• Alexandros Fotopoulos MSc, MBA,
  Chief Technical Officer
• Simona King,
  CFO & Corp. Sec.
• Dr. James M. Wilson M.D., Ph.D.,
  Co-Founder & Chief Scientific Advisor
• Bruce A Goldsmith,
  CEO and President
• Life Sciences Ix, L.P.Fhmls...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Advisors Llc Orbi Med Capit...,
  
• Eliseo Oreste Salinas,
  Chief Res. & Develop Officer
• Mark S Forman,
  CHIEF MEDICAL OFFICER
• Monika Maria Toernsen,
  Chief Commercial Officer
• Stephen P Squinto,
  Head of Research and Dev
• Jill M. Quigley,
  Chief Operating Officer
• Richard Steven Morris,
  Chief Financial Officer
• Gary Romano,
  Chief Medical Officer
• Patrick J Heron,
  Director
• Liam Ratcliffe,
  Director
• Thomas Woiwode,
  Director
• Tadataka Yamada,
  Director
• Edgar B. Cale,
  GC & CORPORATE SECRETARY
• Kathleen Borthwick,
  CFO
• Derrell Porter,
  
• Simona King,
  Chief Financial Officer
• Saqib Islam,
  
• Dolan Sondhi,
  
• Maxine Gowen,
  
• Sandip Kapadia,
  
• Athena Countouriotis,
  
• Michael E. Kamarck,
  Director
• William Chou,
  PRESIDENT AND CEO